Alison M Boyce1. 1. Section on Skeletal Disorders and Mineral Homeostasis, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Building 30 Room 228 MSC 4320, Bethesda, MD, 20982, USA. boyceam@mail.nih.gov.
Abstract
PURPOSE OF REVIEW: Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), and has emerged as an important novel therapy for skeletal disorders. This article examines the use of denosumab in children. RECENT FINDINGS: Considerable safety and efficacy data exists for denosumab treatment of adults with osteoporosis, bone metastases, and giant cell tumors. Pediatric data is limited; however, evidence suggests denosumab may be beneficial in decreasing bone turnover, increasing bone density, and preventing growth of certain skeletal neoplasms in children. Denosumab's effect on bone turnover is rapidly reversible after drug discontinuation, representing a key difference from bisphosphonates. Rebound increased bone turnover has led to severe hypercalcemia in several pediatric patients. Denosumab is a promising therapy for pediatric skeletal disorders. At present, safety concerns related to rebounding bone turnover and mineral homeostasis impact use of denosumab in children. Research is needed to determine if and how these effects can be mitigated.
PURPOSE OF REVIEW: Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), and has emerged as an important novel therapy for skeletal disorders. This article examines the use of denosumab in children. RECENT FINDINGS: Considerable safety and efficacy data exists for denosumab treatment of adults with osteoporosis, bone metastases, and giant cell tumors. Pediatric data is limited; however, evidence suggests denosumab may be beneficial in decreasing bone turnover, increasing bone density, and preventing growth of certain skeletal neoplasms in children. Denosumab's effect on bone turnover is rapidly reversible after drug discontinuation, representing a key difference from bisphosphonates. Rebound increased bone turnover has led to severe hypercalcemia in several pediatric patients. Denosumab is a promising therapy for pediatric skeletal disorders. At present, safety concerns related to rebounding bone turnover and mineral homeostasis impact use of denosumab in children. Research is needed to determine if and how these effects can be mitigated.
Authors: Francis H Glorieux; Leanne M Ward; Frank Rauch; Ljiljana Lalic; Peter J Roughley; Rose Travers Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: George R Matcuk; Dakshesh B Patel; Aaron J Schein; Eric A White; Lawrence R Menendez Journal: Skeletal Radiol Date: 2015-02-26 Impact factor: 2.199
Authors: Louis C Gerstenfeld; Daniel J Sacks; Megan Pelis; Zachary D Mason; Dana T Graves; Mauricio Barrero; Michael S Ominsky; Paul J Kostenuik; Elise F Morgan; Thomas A Einhorn Journal: J Bone Miner Res Date: 2009-02 Impact factor: 6.741
Authors: Mimi I Hu; Ilya G Glezerman; Sophie Leboulleux; Karl Insogna; Rasim Gucalp; Waldemar Misiorowski; Bennett Yu; Paul Zorsky; Diego Tosi; Alberto Bessudo; Arnaud Jaccard; Giuseppe Tonini; Wendy Ying; Ada Braun; Rajul K Jain Journal: J Clin Endocrinol Metab Date: 2014-06-10 Impact factor: 5.958
Authors: S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone Journal: Osteoporos Int Date: 2015-07-23 Impact factor: 4.507
Authors: A Deodati; D Fintini; E Levtchenko; M Rossi; G Ubertini; H Segers; G Battafarano; M Cappa; A Del Fattore Journal: J Endocrinol Invest Date: 2021-07-03 Impact factor: 4.256